Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis.
Anisodamine is an ancient Chinese medicine derived from Tibet as a belladonna alkaloid, which is usually used for improvement of blood circulation in patients with organ phosphorus poisoning or shock. In this study, for the first time, we report its cardioprotective effects on preventing ischemia/reperfusion (I/R) injury of patients with acute myocardial infarction (AMI), and decreasing the myocardial infarction area and severity in heart of Sprague-Dawley (SD) rats. Our results suggest a potential molecular mechanism of anisodamine against the I/R injury in cardiomyocytes is associated with its anti-apoptotic effect. Anisodamine treatment decreases the expression of caspase-3 and caspase-8, and increases Bcl-2/Bax ratio in cardiomyocytes. Our data suggest that anisodamine can provide significant cardioprotection against I/R injury, potentially through the suppression of cardiomyocytes apoptosis.
Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Kun
K
Xing
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China. fuxh9998@163.com.
Xianghua
X
Fu
Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Lingling
L
Jiang
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Yanbo
Y
Wang
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Wei
W
Li
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Xinshun
X
Gu
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Guozhen
G
Hao
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Qing
Q
Miao
Hebei Province Key Laboratory of Molecular Chemistry for Drug, Shijiazhuang City, Hebei Province, China.
Xiaolin
X
Ge
Bethune International Hospital of Chinese PLA, Shijiazhuang City, Hebei Province, China.
Yuhong
Y
Peng
The No.1 Hospital of Baoding City, Baoding City, Hebei Province, China.
Wei
W
Geng
Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Shiru
S
Bai
The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Liye
L
Wei
Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Xile
X
Bi
D000328:Adult; D000368:Aged; D000818:Animals; D017209:Apoptosis; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002460:Cell Line; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012991:Solanaceous Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D012991:Solanaceous Alkaloids; C003922:anisodamine
Acute myocardial infarction; Anisodamine; Apoptosis; H9c2 cells; Ischemia/reperfusion injury